Log In
Print this Print this

bioerodible latanprost implant (Durasert)

  Manage Alerts
Collapse Summary General Information
Company pSivida Corp.
DescriptionSustained-release, bioerodible implant delivering latanoprost into the subconjunctival space of the eye using pSivida's Durasert technology
Molecular Target
Mechanism of Action 
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentPhase I/II
Standard IndicationOcular hypertension
Indication DetailsReduce intraocular pressure in patients with ocular hypertension or glaucoma
Regulatory Designation


Pfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today